With a market capitalization (market cap) of $1.41B — a measure of how much the company is worth — Jade Biosciences, Inc. is the 2354th most valuable company in Healthcare as of August 12, 2026. Shares trade at $23.21, up +3.85% on the day.
of 2,600
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Visit websiteAs of August 12, 2026, Jade Biosciences, Inc. (JBIO) is worth $1.41B — this is its market capitalization, the total value of all its outstanding shares.
Jade Biosciences, Inc.’s market cap is $1.41B, which ranks it #2354 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Jade Biosciences, Inc. (JBIO) shares trade at $23.21, up 3.85% on the day, as of August 12, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025